Malignant pleural effusion Cancer Malignant neoplasm without specification of site
Conditions
Interventions
Randomised controlled trial. Random allocation to:
1. Sterile talc
2. Tetracycline
3. Bleomycin
Sponsors
Department of Health (UK)
Eligibility
Inclusion criteria
Inclusion criteria: Predominantly lung cancer patients with a selection of other cancer patients with malignancy effusions. (This is likely to be mostly breast cancer patients.)
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study should provide information as to which of these most commonly used agents for medical pleurodesis is most effective in preventing further malignant pleural effusions. It should provide information on which agent if any is associated with more prolonged survival. It should provide information on issues such as pain and infection rates during pleurodesis with these agents. Hopefully, these data will lead to an evidence based choice of sclerosing agent for cancer patients with malignant pleural effusions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed